Final skin toxicity and patient‑reported outcomes results from PRIME: A randomized phase 3 study of panitumumab + FOLFOX4 for 1st‑line metastatic colorectal cancer Jean‑Yves…

Predictive value of skin-toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of 5 clinical trials Jordan…

MANAGEMENT OF OSTEOPOROSIS Professor Opinder Sahota Consultant Physician QMC, Nottingham Financial Turmoil £15 billion cost saving over the next 3 yrs £1.5 billion for…

Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from a phase 2 study Jean-Yves Blay1, Sant Chawla2, Javier Martin Broto3, Edwin Choy4,…

ASCO 2006 Supportive Care John Glaspy, MD Sanders Chair in Cancer Research Jonsson Comprehensive Cancer Center Professor of Medicine UCLA School of Medicine UCLA Supportive…

Panitumumab Efficacy and Patient-Reported Outcomes in Metastatic Colorectal Cancer Patients With Wild-Type KRAS Tumor Status Rafael G. Amado, MD;1 Michael Wolf, MS;1 Dan…

A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of a Monoclonal Antibody to PCSK9, SAR236553/REGN727, in Patients with Primary Hypercholesterolemia…

Phase II Trial of Ipilimumab Monotherapy in Melanoma Patients with Brain Metastases Lawrence DP et al. Proc ASCO 2010;Abstract 8523. Lawrence DP et al. Proc ASCO 2010;Abstract…

A Randomized, Phase 1/2 Trial of AMG 102 or AMG 479 in Combination With Panitumumab vs Panitumumab Alone in Patients With Wild‑Type KRAS Metastatic Colorectal Cancer (mCRC):…

Final skin toxicity and patient‑reported outcomes results from PRIME: A randomized phase 3 study of panitumumab + FOLFOX4 for 1st‑line metastatic colorectal cancer Jean‑Yves…